পিত্ত নলীৰ কেন্সাৰ
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
ক’ত যাব
ভাৰতৰ 4 খন হস্পিটেলত এই ট্ৰায়েলৰ বাবে ৰোগী লোৱা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.
স্পনছৰ: Jazz Pharmaceuticals
ClinicalTrials.gov-ত NCT06282575
ৰেজিস্ট্ৰিত শেষবাৰ আপডেট কৰা হৈছে 14 Sep 2026 · আমাৰ দ্বাৰা পঢ়া হৈছে 20 Oct 2026